On April 22, 2022 This weekend, Madrid is hosting the "Generating Evidence and Sharing Experience (GESE)" Congress, organized by PharmaMar (MSE:PHM), reported that where leading European oncologists and medical specialists will meet to share the latest advances in the treatment and diagnosis of this disease (Press release, PharmaMar, APR 22, 2022, View Source [SID1234612864]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Soft Tissue Sarcoma (STS) is a group of solid tumors that can develop anywhere in the body, forming in soft tissues such as cartilage, fat, muscle, nerves, blood vessels or the deep tissues of the skin. Although STS can occur anywhere in the body, it usually occurs (43%) in the arms and legs.

Sarcoma is a type of cancer that encompasses more than 60 different subtypes. They are rare tumors that can appear at any time in life. Within localized sarcomas, the probability of survival, with appropriate treatment, is around 65% to 70%. This heterogeneity makes it difficult for specialists to decide on the treatment to combat the disease.

The attendees, experts from France, Italy, Germany, Austria, Holland, Switzerland, Portugal and Spain, will address topics such as the most avant-garde options for treatment, ultra-rare pathologies, new combinations, and the patient’s quality of life as an essential issue in the evolution of sarcomas, among others.

STS is one of the most difficult tumors to treat. Not only because of the difficulty required for its diagnosis -where the patient plays a very important role- but also because there are several different professionals who must deal with the treatment of these tumors in a multi-disciplinary manner.